Philips extends its mobile C-arm range with Zenition 30, alleviating staff shortages by empowering surgeons with greater personalization and control

Philips Zenition 30 in use

Philips Zenition 30 product photo

September 13, 2023

  • Offering surgeons greater flexibility, control, and personalization in C-arm operation and image acquisition, Philips’ new Zenition 30 reduces dependency on technician support for a wide variety of minimally invasive procedures  
  • Advanced imaging algorithms contribute to outstanding image quality and dose efficiency

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 3000 – Zenition 30 [1], the latest addition to the company’s highly versatile Zenition mobile C-arm series. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures.

The Zenition 30 gives surgeons a greater level of control, empowering them to work more autonomously and independently. By reducing dependency on support staff, Zenition 30 helps alleviate the staff shortages faced by many hospitals, while its workflow-enhancing features and excellent image quality allow surgeons to deliver high-quality care to more patients. The launch of the Zenition 30 follows the recent launch of the Philips Zenition 10 C-arm [2].

“Based on our Zenition platform’s proven ease of use and workflow efficiency, the new Zenition 30 offers a unique combination of personalized control and image clarity to enhance the speed and accuracy of decision-making for a range of clinical procedures at a price point that meets today’s economic and business goals,” said Mark Stoffels, General Manager, Philips Image Guided Therapy Systems.

High-quality imaging
Zenition 30 offers versatility for a range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures. Featuring Philips’ latest-generation flat detector technology, advanced imaging algorithms, and personalized user profiles, the new system delivers superior image quality, dose efficiency, and workflow customization. From the moment a surgeon logs on, the Zenition 30 automatically adjusts to their preferred settings and way of working, contributing to fewer manual adjustments and more first-time-right imaging. In addition to rapid set-up and protocol selection, the Zenition 30 also offers surgeons much greater control over C-arm positioning during surgical procedures.

In independent usability studies involving clinicians around the world who were offered hands-on experience of the Zenition 30 in simulated environments, 95% said they believed its enhanced surgeon control would allow them to work independently [3], while 84% believed that Zenition 30’s personalized image quality profiles meant fewer images might be needed during a procedure because the first image already incorporates their preferred settings [4].

As part of its commitment to doing business sustainably and helping its customers make responsible choices, Philips has designed the Zenition 30 to have a 25% increased product lifetime [5] and also has a refurbished program available, making it ‘circular-ready’ for repair, refurbishment, and recycling [5].

Other C-arm systems in Philips’ Zenition series are the Zenition 50, Zenition 70, and the recently launched Zenition 10 [2].

[1] Zenition 30 mobile C-arm systems are available for sale in a limited number of countries. Please check with a local representative for availability in your market. Pending 510 (k) not available for sale in the USA.
[2] Zenition 10 mobile C-arm system is not available in the USA.
[3] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 37 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.
[4] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 50 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.
[5] Compared to its predecessor, BV Endura 2.3.

For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

6 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

7 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

7 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

8 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago